Exploring Differentially Expressed Genes and Immune Modulation in Diffuse Large B-Cell Lymphoma through RNA...

Area of Science:

• Oncology
• Genomics
• Immunology

Background:

• Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive non-Hodgkin lymphoma.
• Treatment resistance and relapse are significant challenges in DLBCL management.
• Understanding molecular alterations is key to improving DLBCL outcomes.

Purpose of the Study:

• To identify differentially expressed genes in DLBCL at the transcriptome level.
• To investigate molecular pathways associated with DLBCL pathogenesis.
• To uncover potential novel therapeutic targets for DLBCL.

Main Methods:

• RNA sequencing was performed on DLBCL patients and healthy volunteers.
• Differential gene expression analysis was conducted using the DESeq2 R package.
• Pathway enrichment analysis utilized the Reactome database.

Main Results:

• 73 differentially expressed genes were identified between DLBCL patients and controls.
• 70 genes were downregulated, and 3 genes were upregulated in DLBCL.
• Significantly downregulated pathways included antimicrobial humoral response and neutrophil degranulation.

Conclusions:

• Downregulation of specific pathways may contribute to DLBCL progression and immune evasion.
• These findings provide novel insights into molecular mechanisms underlying DLBCL.
• Identified pathways and genes represent potential targets for future DLBCL therapies.